Clinical Trial Update: Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating safety, tolerability, and efficacy of ustekinumab for gastrointestinal inflammation related to common variable immunodeficiency (CVID…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Common Variable Immunodeficiency
• Cvid Enteropathy
• Gastrointestinal Inflammation Associated with Cvid

Drugs mentioned

• USTEKINUMAB (USTEKINUMAB)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Gastrointestinal Inflammation Associated With CVID, CVID Enteropathy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-08-24